补肾促卵方治疗早发性卵巢功能低下导致不孕症的临床研究
|
摘要
研究补肾促卵方治疗早发性卵巢功能低下导致不孕症的临床疗效。选择2016年10月—2018年9月于中国中医科学院西苑医院及中国中医科学院门诊部就诊的90例早发性卵巢功能低下导致不孕症患者,按1∶1随机分为试验组和对照组。试验组予以补肾促卵方,对照组予以补佳乐+克罗米芬+黄体酮,观察2组排卵率、妊娠率、性激素水平、中医症候积分变化。试验组治疗前后各项指标均有改善且具有显著性差异(P<0. 05)。总有效率试验组为95. 35%,对照组为88. 37%,有显著性差异(P<0. 01)。与对照组相比,试验组在改善FSH及AMH水平、增加窦状卵泡个数、改善中医症候方面优于对照组且有显著性差异(P<0. 05);在排卵率、妊娠率、改善LH及E2水平方面疗效相当,无显著性差异。结果表明补肾促卵方临床安全性高,疗效确切,值得推广使用。
To analyze the clinical efficiency of traditional Chinese medicine( TCM) Bushen Culuan Decoction in treating anovulatory infertility due to premature ovarian insufficiency( POI). A total of 90 eligible cases were randomly divided into experimental group and control group. The 45 cases in the experimental group took Bushen Culuan Decoction,while the other 45 cases in the control group took estradiol valerate( Progynova),clomiphene( Clomiphene Citrate tablet) and progesterone. The ovulation rate,pregnancy rate,serum hormone level and TCM symptom scale were tested to evaluate the effectiveness of the two therapies. All indexes in experimental group improved significantly after treatment( P<0. 05). The total effectiveness rate was 95. 35% in experimental group and 88. 37% in control group,with a significant difference( P<0. 01). Compared with control group,experimental group had better results in depressing FSH level,elevating AMH level,increasing number of AFC and improving TCM symptom,with significant differences( P < 0. 05). There was no significant difference between experimental group and control group in ovulation rate,pregnancy rate,depressing LH level or elevating E2 level. In this study,Bushen Culuan Decoction is proved to be safe and effective for clinical use in treating infertility due to POI.
To analyze the clinical efficiency of traditional Chinese medicine( TCM) Bushen Culuan Decoction in treating anovulatory infertility due to premature ovarian insufficiency( POI). A total of 90 eligible cases were randomly divided into experimental group and control group. The 45 cases in the experimental group took Bushen Culuan Decoction,while the other 45 cases in the control group took estradiol valerate( Progynova),clomiphene( Clomiphene Citrate tablet) and progesterone. The ovulation rate,pregnancy rate,serum hormone level and TCM symptom scale were tested to evaluate the effectiveness of the two therapies. All indexes in experimental group improved significantly after treatment( P<0. 05). The total effectiveness rate was 95. 35% in experimental group and 88. 37% in control group,with a significant difference( P<0. 01). Compared with control group,experimental group had better results in depressing FSH level,elevating AMH level,increasing number of AFC and improving TCM symptom,with significant differences( P < 0. 05). There was no significant difference between experimental group and control group in ovulation rate,pregnancy rate,depressing LH level or elevating E2 level. In this study,Bushen Culuan Decoction is proved to be safe and effective for clinical use in treating infertility due to POI.
引文
[1]The ESHRE Guideline Group on POI,Webber L,Davies M,et al.ESHRE guideline:management of women with premature ovarian in sufficiency[J].Hum Reprod,2016,31(5):926.
[2]马堃,刘雁峰,何军琴,等.补肾活血方案治疗排卵障碍性不孕不育的多中心随机双盲对照临床研究[J].中国中药杂志,2015,40(20):3911.
[3]李蓉,乔杰.生殖内分泌疾病诊断与治疗[M].北京:北京大学医学出版社,2012:356.
[4]罗颂平.中医妇科学[M].北京:高等教育出版社,2008:117.
[5]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:239.
[6]国家中医药管理局.中医病症诊断疗效标准[S].北京:中国医药科技出版社,2012:215.
[7]陈士岭,周星宇.早发性卵巢功能不全的临床诊治进展[J].山东大学学报:医学版,2018,56(4):1.
[8]中华医学会妇产科学分会绝经学组.早发性卵巢功能不全的激素补充治疗专家共识[J].中华妇产科杂志,2016,51(12):881.
[9]Collaborative Groupon Epidemiological Studies of Ovarian Cancer.Menopause hormone use and ovarian cancer risk:individual participant Meta-analysis of 52 epidemiological studies[J].Lancet,2015,385:1835.
[10]Lobo R A.Hormone-replacement therapy:current thinking[J].Nat Rev Endocrinol,2017,13:220.
[11]张洁琼,张琴,孟莉.激素替代治疗与乳腺癌发生风险概述[J].中国妇幼保健,2015(30):6669.
[12]胡艳玲,张金磊,侯晓雯,等.雌孕激素替代治疗与卵巢癌发病风险相关性的Meta分析[J].肿瘤学杂志,2016,22(7):549.
[13]Ben-Nagi J,Panay N.Premature ovarian insufficiency:how to improve reproductive outcome?[J].Climacteric,2014,17:242.
[14]徐海静,孙赟.中国赠卵现状及中、外赠卵政策比较[J].生殖与避孕,2014,34(2):93.
[2]马堃,刘雁峰,何军琴,等.补肾活血方案治疗排卵障碍性不孕不育的多中心随机双盲对照临床研究[J].中国中药杂志,2015,40(20):3911.
[3]李蓉,乔杰.生殖内分泌疾病诊断与治疗[M].北京:北京大学医学出版社,2012:356.
[4]罗颂平.中医妇科学[M].北京:高等教育出版社,2008:117.
[5]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:239.
[6]国家中医药管理局.中医病症诊断疗效标准[S].北京:中国医药科技出版社,2012:215.
[7]陈士岭,周星宇.早发性卵巢功能不全的临床诊治进展[J].山东大学学报:医学版,2018,56(4):1.
[8]中华医学会妇产科学分会绝经学组.早发性卵巢功能不全的激素补充治疗专家共识[J].中华妇产科杂志,2016,51(12):881.
[9]Collaborative Groupon Epidemiological Studies of Ovarian Cancer.Menopause hormone use and ovarian cancer risk:individual participant Meta-analysis of 52 epidemiological studies[J].Lancet,2015,385:1835.
[10]Lobo R A.Hormone-replacement therapy:current thinking[J].Nat Rev Endocrinol,2017,13:220.
[11]张洁琼,张琴,孟莉.激素替代治疗与乳腺癌发生风险概述[J].中国妇幼保健,2015(30):6669.
[12]胡艳玲,张金磊,侯晓雯,等.雌孕激素替代治疗与卵巢癌发病风险相关性的Meta分析[J].肿瘤学杂志,2016,22(7):549.
[13]Ben-Nagi J,Panay N.Premature ovarian insufficiency:how to improve reproductive outcome?[J].Climacteric,2014,17:242.
[14]徐海静,孙赟.中国赠卵现状及中、外赠卵政策比较[J].生殖与避孕,2014,34(2):93.